The FDA on Friday authorized the use of the Alzheimer’s drug lecanemab, the first drug clearly shown to slow the progress of the debilitating brain disease.
But the treatment will not be widely available at first, as insurers are not expected to cover it until the agency reviews additional evidence about the drug’s effectiveness.
That review may come later this year. Yet even then, policy experts warn that the health-care system will have trouble accommodating — and paying for — treatment of the millions who will be eligible.
